Pharmacogenomics and the Most Commonly Prescribed Drugs of 2011

, ,
Pharmacy Times, December 2012 Heart Health, Volume 78, Issue 12

Pharmacogenomics and the Most Commonly Prescribed Drugs of 2011

David F. Kisor, BS, PharmD, RPh

Professor of Pharmacokinetics

Chair of the Department of Pharmaceutical and Biomedical Sciences

Raabe College of Pharmacy, Ohio Northern University

Ada, Ohio

Caitlin Munro, PharmD Candidate

Raabe College of Pharmacy, Ohio Northern University

Ada, Ohio

Emily Loudermilk, PharmD Candidate

Raabe College of Pharmacy, Ohio Northern University

Ada, Ohio

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty: David F. Kisor, BS, PharmD, RPh; Caitlin Munro, PharmD Candidate; and Emily Loudermilk, PharmD Candidate

Pharmacy Times Office of Continuing Professional Education (PTOCPE): Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff: Jennifer Whartenby and David Allikas

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify those agents among most commonly prescribed drugs of 2011 that include genomic biomarker information within product labeling and FDA resources.
  • Describe the context of the biomarker related to the specific drug.
  • Identify the biomarker—drug relationships that impact drug dosing.
  • Describe biomarker—drug relationships relative to pharmacokinetics and/or pharmacodynamics and understand their limitations.

Type of activity: Knowledge

Release date: December 10, 2012

Expiration date: December 10, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online

Click here to view this activity.